Ligand Pharma (LGNXZ) Stock Price, News & Analysis
Company Description
Ligand Pharma (OTC Link: LGNXZ) is a publicly traded company.
LGNXZ stock has gained 42.9% over the past year. Shares last traded at $0.0020.
On a trailing twelve-month basis, Ligand Pharma reported revenue of $268.1M with net income of $124.5M and diluted earnings per share of $6.13. The company operates at a net profit margin of 46.4%.
This page provides a comprehensive overview of LGNXZ stock, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Ligand Pharma (LGNXZ) stock last traded at $0.0020. Over the past 12 months, the stock has gained 42.9%.
LGNXZ Rankings
Latest News
SEC Filings
Ligand Pharma has filed 5 recent SEC filings, including 3 Form 4, 1 Form 144, 1 Form 8-K. The most recent filing was submitted on July 6, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LGNXZ SEC filings →
Financial Highlights
Ligand Pharma generated $268.1M in revenue over the trailing twelve months, operating income reached $41.0M (15.3% operating margin), and net income was $124.5M, reflecting a 46.4% net profit margin. Diluted earnings per share stood at $6.13. The company generated $49.4M in operating cash flow. With a current ratio of 22.23, the balance sheet reflects a strong liquidity position.